StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN – Free Report) in a research note published on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
FibroGen Stock Performance
Shares of FGEN stock opened at $0.37 on Monday. FibroGen has a 1 year low of $0.30 and a 1 year high of $2.93. The firm has a market capitalization of $37.25 million, a PE ratio of -0.15 and a beta of 0.70. The stock has a fifty day moving average of $0.39 and a two-hundred day moving average of $0.83.
FibroGen (NASDAQ:FGEN – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to analyst estimates of $33.00 million. During the same period in the previous year, the company earned ($0.65) EPS. Equities research analysts predict that FibroGen will post -0.91 earnings per share for the current fiscal year.
Hedge Funds Weigh In On FibroGen
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Read More
- Five stocks we like better than FibroGen
- What Does a Stock Split Mean?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- How to Invest in the Best Canadian Stocks
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Best Stocks Under $10.00
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.